Evolent Health (NYSE:EVH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 33.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $222.06 million which beat the analyst consensus estimate of $216.92 million by 2.37 percent. This is a 6.95 percent decrease over sales of $238.63 million the same period last year.
Canaccord Genuity Maintains Buy on Bicycle Therapeutics, Raises Price Target to $40
Canaccord Genuity maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and raises the price target from $36 to $40.
